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Epilepsy and anticonvulsants in pregnancy
Peter Turnpenny (Consultant Clinical Geneticist)
Royal Devon & Exeter Hospital, Exeter, Devon, UK
The possible teratogenic effects of anticonvulsant drugs has attracted considerable clinical and research interest over a long pe-
riod. A substantial medical literature has provided convincing evidence for an increased incidence of congenital malformations
in the offspring of mothers taking these drugs, and 6–10%, or a two- to three-fold increase, is a generally quoted figure1, 2. Over
the last two decades the most popular drugs have been sodium valproate and carbamazepine, succeeding but not completely
replacing phenobarbitone and phenytoin. Valproate was first licensed for use in the UK in 1974 and the first reports of an
increased risk of neural tube defect and cleft palate emerged in 1982/83. Subsequently further non-specific birth defects were
described in association with valproate and reports of a characteristic facial phenotype appeared. Despite the growing literature,
including papers in major medical journals, anecdotal evidence has suggested that the general awareness of problems associated
with the use of these drugs in pregnancy is poor. Many mothers claiming to have affected children, complain at having received
little or no information, or were given complete reassurance.
In assessing the teratogenic risks of anticonvulsants research has focused heavily on congenital malformations. However, the
anecdotal experience of some clinicians, particularly clinical geneticists who see many dysmorphic children for assessment and
diagnosis, points to a possible increased frequency of neurodevelopmental delay. In my practice four children diagnosed with
a fetal anticonvulsant syndrome (each had been exposed to sodium valproate and one of the four to carbamazepine in addition)
had varying degrees of learning and behaviour problems as well as speech and language delay. ‘Expressive’ speech delay was
more markedly affected than ‘receptive’, consistent with the findings of Christianson et al.3 The behaviour disorder of three of
these children also had a similar behaviour pattern, consisting of a socially inhibiting fear of strange environments and crowds.
Whilst reference has been made to neurodevelopmental outcome in the published literature3–7, there are no controlled studies
which allow a definitive conclusion to be drawn.
In the four cases mentioned all had developed significant myopia as pre-school children, which has not been previously re-
ported. These observations justified further clinical research and, with the help of the National Fetal Anti-Convulsant Syndrome
Association, the Exeter and Aberdeen FACS Study was conceived. This culminated in clinical assessment of 58 children from
38 families, involving a detailed pregnancy and medical history as well as examination for dysmorphic features and clinical
photography, including the parents where possible. Chromosome analysis and Fragile-X syndrome studies were undertaken, or
results acquired from their medical records, which in all cases tested were negative. All the clinical photographs were scrutinized
by two independent experts besides those of us undertaking the study, and 53 of the children were judged to be affected with
a fetal anticonvulsant syndrome. Importantly, major congenital malformations were present in a minority of some 20 children;
there were two cases of neural tube defects but not a single case of clefting. A history of learning and behavioural difficulties,
however, was clearly documented in the majority—only four subjects had neither a learning or behavioural disorder. The study
highlighted some previously unreported features, namely a high frequency of joint laxity, myopia and astigmatism. In some
cases a visual defect in older children had not been recognized at all.
Although this study represents biased ascertainment of cases of fetal anticonvulsant syndromes, by virtue of self selection
through the patient support group, the results suggest, along with other anecdotal evidence, that neurodevelopmental delay may
be a very significant, yet poorly recognized, aspect of fetal exposure to these drugs. And, importantly, our experience suggests
these sequelae may occur in the absence of physical birth defects. The implications are very considerable because the burden
for affected families, as well as educational and social services, is long term compared with the consequences of a physical birth
defect which may be amenable to simple and curative surgical treatment.
Those of us in clinical genetics with an interest in this problem met briefly at our annual meeting last September. This semi-
nar, drawing together representatives from all the relevant medical disciplines, is the outcome. There is an urgent need to discuss
the issues across speciality boundaries in order to both identify critical research questions to be addressed and improve services
available to all pregnant women on anticonvulsant medication.
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The Glasgow experience
Eleanor Guthrie
1448 Dumbarton Road, Glasgow, Scotland
Greater Glasgow Health Board provides services for a population of 912 500. It is likely that 4562–9125 (0.5–1.0%) of these
people have epilepsy, approximately half of whom will be female.
Medical services for women with epilepsy are provided by two specialist epilepsy services, three obstetrics units, one pae-
diatric/genetic unit, 624 GPs and their practice teams. Some of these providers also serve populations that extend well beyond
Glasgow’s boundaries.
As a Glasgow General Practitioner who has worked within one of the specialist units, I am aware of the many problems faced
by both women with epilepsy, and service providers in trying to deliver a consistent standard of high-quality care. We currently
have a system of care that links poorly across primary, secondary and tertiary services for a variety of reasons. Additionally we
need to link more closely with the voluntary sector (in Scotland this is the Epilepsy Association of Scotland), and the social
services.
The ‘average GP’ with 2000 patients cares for between 10 and 12 people with active epilepsy. In a year he can expect to refer
two patients with a possible diagnosis of epilepsy, one of whom will turn out to have epilepsy. These small numbers make it
difficult for an individual general practitioner to develop expertise with the complex issues involved in caring for women with
epilepsy.
In Glasgow we can expect about 50–60 births to women with epilepsy per year. These women are cared for by three obstetric
units who each provide care for these patients in different ways. A GP will only care for such a patient once every 12 years.
As it is only the 30% of women with epilepsy which is difficult to control who attend specialist epilepsy units, the majority
of women in child-bearing years can expect to have no contact with a specialist prior to and during child-bearing years.
The numbers described above illustrate the formidable organizational issues that need to be overcome. The problems faced
by Glasgow are by no means unique and need to be resolved to allow women with epilepsy to receive the best possible care.
Outcome of pregnancy in women with epilepsy with regard to malformation
Tara Montgomery∗, S. Fairgrieve∗, P. Jonas∗, M. Jackson†, J. Burn∗ & S. A. Lynch∗
∗Northern Genetics Service, 19 Claremont Place, Newcastle upon Tyne NE2 4AA, UK; †Department of
Neurology, Royal Victoria Infirmary, Newcastle upon Tyne, UK
As part of an ongoing prospective population-based study, detailed information is collected on all pregnant women with epilepsy
in the old Northern Region. Over two years 396 women have been notified: of these 70% were on monotherapy, 14% on
polytherapy and 16% were on no anticonvulsants. Of those on monotherapy, 52% were on carbamazepine, 35.5% on valproate,
9.5% on phenytoin, 2% on lamotrigene and 1% on phenobarbitone. There were 60% of women receiving care for their epilepsy
from their GP. Less than 40% reported receiving advice regarding pregnancy and epilepsy, and this did not rise significantly
for multips. Fewer than half were planned pregnancies. Guidelines for folic acid supplementation and vitamin K useage were
poorly complied with. There have been two medical terminations for spina bifida, both were taking sodium valproate and one
was also taking carbamazepine. Apart from the two cases of spina bifida, there were a number of other malformations amongst
the babies exposed to anticonvulsants including one child with phocomelia whose mother was on sodium valproate and one
child with short ribs whose mother was on valproate and lamotrigine. Phocomelia is a well-recognised valproate-associated
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malformation. Rib anomalies have been associated with valproate in both human and animal studies but we are aware of
another case of rib anomalies reported in association with lamotrigine and carbamazepine. We have identified four babies with
malformations who were not exposed to antiepileptic medication. The overall malformation rate in women with epilepsy was
1.6 times our general population rate, supporting previous observations that this group of women are at high risk of having
infants with malformations. Despite this, they currently appear not to receive optimal care. We are trying to address this by a
programme of education and the use of guidelines and epilepsy care nurses. We hope to continue a more detailed study of the
offspring of these women looking at their developmental outcome and studying any dysmorphic features.
UK Epilepsy and pregnancy register
Dr Aline Russell∗, Dr Jim Morrow†, Dr John Craig‡, Dr Linda Parsons§, Dr Patric Morrison¶, Dr Iain
Robertson‖ & Dr Eleanor Guthrie∗∗
∗Southern General Hospital; †Royal Victoria Hospital, Belfast; ‡Royal Victoria Hospital, Belfast; Glasgow;
§Luton and Dunstable Hospital; ¶Belfast City Hospital; ‖Sharoe Green Hospital, Preston, UK; ∗∗1448
Dumbarton Rd, Glasgow
Teratogenesis is an important consideration when prescribing antiepileptic drugs (AEDs) in women of child-bearing age. These
risks may increase with dosage and the number of AEDs taken. Five new AEDs have been licensed for use in the UK since 1989
with no useful data on their safety in pregnancy although animal studies have been initially reassuring for some. In addition
many women are prescribed the newer AEDs in combination with other AEDs which may increase risks. In order to try and
address these problems a confidential prospective observational registration and follow-up study of the relative safety of the
newer AEDs as been established with ethical approval in the UK since 1996. Any woman with epilepsy, whether currently
taking AEDs or not and who becomes pregnant, is eligible for inclusion on the register. Reporting of cases is encouraged from
neurologists and other specialists providing epilepsy services, specialist epilepsy nurses, obstetricians, midwives and general
practitioners. This year additional funding has allowed the setting up of a freephone number—0800 3891248—to enable eligible
women to self refer. To date over 1000 women have been registered (90% prospectively) with outcome data on over 400. Of these
4% took no AED before or during pregnancy and 56% were on monotherapy. A healthy baby was born in 83% pregnancies
with a spontaneous pregnancy loss of 12%. Of live births or abortions, 5% have resulted in a major structural birth defect.
Lamotrigine was the most frequently prescribed newer AED (N = 109) with a major structural defect occurring in 1 of
43 patients on lamotrigine monotherapy. The remaining monotherapy-associated abnormalities occurred in women on sodium
valproate monotherapy (N = 38). All other structural abnormalities reported occurred in patients on polytherapy. We have,
therefore, established an effective method for collecting data which in time will allow more accurate counselling of women
planning a pregnancy while receiving treatment for epilepsy.
Clinical pharmacology of antiepileptic drugs in pregnancy
George Mawer∗, Jill Clayton-Smith† & Helen Coyle∗
∗David Lewis Centre for Epilepsy, Cheshire, UK; †Regional Genetic Service, St Mary’s Hospital, Manchester, UK
A woman with epilepsy embarking on pregnancy is most likely to be taking carbamazepine or sodium valproate; these are the
standard drugs against focal and generalized epilepsies, respectively. Phenytoin use is waning and, when pregnancy is foreseen,
there is appropriate caution about the use of the newer drugs introduced since 1989.
Many studies of pregnancy outcome relate to phenobarbitone and phenytoin. Some report increased complications of preg-
nancy (for example vaginal bleeding, spontaneous abortion, pre-eclampsia, operative delivery and neonatal haemorrhage) but
there is much variation between studies.
The incidence of structural defects in the progeny is increased (4–6% compared with 2–3% in the general population); the
likelihood of defect increases with the number of drugs taken and with the dose. Omtzigt et al.1 for example, found an increase
in the risk of spina bifida with higher doses of sodium valproate. Monotherapy at the minimum dose for acceptable seizure
control is thus recommended.
Since 1975, dysmorphic states with cranio-facial features and mis-aligned digits have been recognised; some may be drug-
specific but lack of accepted definitions means the incidence is not known. An association with neuro-developmental delay is
suspected and causes special concern.
We have monitored the outcome of pregnancy in patients attending the Central Manchester Epilepsy Clinic since 1990.
Infants are assessed by JC-S and graded 1, 2 or 3 for impaired development, dysmorphic features and structural defects. Assess-
ment has been made of 32 of 56 infants; 25 of 32 had been exposed to monotherapy with carbamazepine (8), lamotrigine (2),
phenytoin (3) or sodium valproate (12). The incidence of abnormality was higher than that genrally reported in the offspring of
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mothers with epilepsy-impaired development in 12 of 32 (38%): dysmorphic features in 14 of 32 (44%): structural defects in 7
of 32 (22%)—but the majority of infants were mildly affected (graded 1). Moderate (2) and severe (3) abnormalities were found
mainly in the offspring of mothers who conceived whilst receiving sodium valproate at a dose of more than 800 mg day−1.
Our study has no control group and is biased towards mothers with difficult-to-manage epilepsy. An ideal study would recruit
from primary care or hospital antenatal clinics to avoid bias and compare with matched controls; every infant would be assessed.
The impact of drug + epilepsy would be revealed but differences due to drugs would still be confounded with differences due
to epileptic syndromes. Dose/response relationships within drug-syndrome groups would clarify the role of the drug.
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Fetal anticonvulsant syndromes: an overview
Jill Clayton-Smith
Regional Genetic Service, St. Mary’s Hospital, Manchester, UK
The incidence of birth defects amongst the children of epileptic mothers is around 6–7%, about twice to three times that of
the normal population. There may be serveral reasons for this including genetic predisposition, effect of seizures during preg-
nancy and teratogenic effects of anticonvulsants used to control the epilepsy. There is now firm evidence for the latter both
from animal studies and from clinical studies of exposed infants. The data is, however, incomplete since there have been no
good long-term follow-up studies to document in particular the developmental and neuropsychological problems encountered in
children exposed to anticonvulsants during pregnancy. This presentation documented the clinical features in a series of patients
referred to the Department of Clinical Genetics at St. Mary’s Hospital. As such it is anecdotal, and the sample is biased because
of the mode of ascertainment. Documentation of the problems in these individuals does, however, aid delineation of the fetal
anticonvulsant syndromes.
Fetal phenytoin syndrome was the first anticonvulsant syndrome to be recognised as an entity by Hanson in 1978. Of infants
exposed to phenytoin in utero 10% will show significant adverse effects, which include intra-uterine growth retardation, dis-
tinctive facies with flat nasal bridge, hypertelorism and prominent cupid’s bow to upper lip, cleft lip and palate, congenital heart
defects and hypoplasia of the distal phalanges and fingernails. Developmental delay is also a feature. Milder effects will be
shown by 30% of infants and the literature suggests that 60% of infants exposed to phenytoin will not show any adverse effects,
although no long-term studies have been carried out to follow up development.
Several reports have linked exposure to carbamazepine in utero with birth defects. The commonest birth defects observed
include spina bifida and orofacial clefting. Jones et al. (1989) suggested that there was a specific ‘carbamazepine face’ but
observation of our own patients did not confirm this.
Fetal valproate syndrome was the commonest condition observed amongst our own cohort of patients. The pattern of abnor-
malities seen in infants exposed to valproic acid in utero was documented by DiLiberti et al. (1984) and our observations in a
series of infants exposed to valproate monotherapy confirm and extend these findings. The clinical features include characteris-
tic facies with a prominent metopic suture and tall forehead with bifrontal narrowing. There is a flat nasal bridge and epicanthic
folds are common in younger children. The eyebrows are often neat and arched, with a medical deficiency, the nose is short
and anteverted, there may be a prominent groove of skin below the eyes and the upper lip is thin and the mouth downturned.
The lower lip is everted, giving a characteristic facial profile and the philtrum is flat. The face is more obvious in younger chil-
dren and becomes less remarkable with age. The congenital malformations associated with the syndrome include neural-tube
defects, usually low lumbosacral spina bifida, cleft palate and congenital heart disease. (A very specific defect, aberrant origin
of the pulmonary artery, was seen in one of our patients). Radial-ray defects are common with high doses of valproate and
other limb defects include lobster-claw deformity, and pre-axial polydactyly. The digits may be slim and the toes are frequently
overlapping. We remarked that the lower-limb musculature appeared poor in many patients and there was marked joint laxity.
Abdominal wall defects, genito-urinary abnormalities and tracheomalacia were also seen. Finally, we have seen three patients
with iris coloboma, a complication not hitherto reported in the literature.
The natural history of fetal valproate syndrome was described. Pregnancy is usually uneventful and most infants have a normal
birth weight. After birth there may be symptoms of drug withdrawal with jitteriness, hypoglycaemia and feeding difficulty.
Thereafter, growth is usually fairly good and most children have normal growth parameters. There is acquired microcephaly in
some patients but this is not the rule. Motor milestones are often normal or mildly delayed, with joint laxity causing difficulty
with walking. Speech delay is often the first problem which brings children to medical attention. Developmental delay is often
not apparent until school age, and the majority of the children we observed were statemented for special educational needs.
Finally, several children had been diagnosed to be hyperactive or were on treatment for attention deficit hyperactivity disorder.
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We attempted to correlate the degree of problems seen in individual children to the dose of valproate they were exposed to
during pregnancy and did this by devising a simple scoring system for adverse effects. This did give a positive correlation with
the worst affected infants having been exposed to higher doses. It also indicated that maternal factors seem important, as some
mother seem to be able to take relatively high doses of sodium valproate without risk to their offspring, whilst others have
children with signs of fetal valproate syndrome even when taking a lower dose.
The fact that some of the features of the fetal valproate syndrome are so specific, e.g. the site of the neural-tube defects,
radial-ray defects and specific heart defects, suggests that valproic acid may be interfering in specific developmental pathways
rather than acting as a general ‘poison’ to the embryo. It has been suggested that valproate may interfere in some with the action
of specific developmental genes such as the HOX gene group. We showed a fetus with an extra set of ribs, which might support
this theory.
Our data, though anecdotal, is of concern, particularly the incidence of developmental and neuropsychological problems
which are not apparent in early infancy. Further prospective controlled studies are merited to study these effects in more detail.
BEA survey of women with epilepsy (Crawford & Lee, Seizure 1999 June)
Pamela Crawford MB, ChB, MD, FRCP
Consultant Neurologist, Director of the Special Centre for Epilepsy, York, UK; Visiting Professor of Community
Neurological Studies, Leeds Metropolitan University, Leeds, UK; Department of Neurosciences, York District
Hospital, York Y03 7HE, UK
This study reports the results of a questionnaire survey of female members of the British Epilepsy Association. The women
were asked about their concerns with their epilepsy with respect to being female, and in particular asking about information
relating to important topics such as contraception and pregnancy. A qeustionnaire was sent to 6000 BEA women members of
whom 1855 (31%) replied.
Of the women 880 (47%) already had children, but one in ten of these were planning to have further children. Overall 441
(23%) of women were planning to have children, 169 (9%) within the next 2 years.
The women were asked about the advice they had received about pregnancy (Table 1). Six hundred and thirty seven (34%)
claimed they had not received any advice and 459 (25%) had not discussed pregnancy with anyone. Amongst those who had
already had children, 232 (38%) claimed not to have received any advice about pregnancy and epilepsy and only 210 (24%)
had discussed the issues before conception with a doctor. The women planning to have children over the subsequent 2 years
received the greatest amount of advice about epilepsy and pregnancy, although 34 (20%) still claimed not to have received any
advice. Many women intending to have children in the next 2 years felt they still had unanswered questions relating to their
epilepsy and pregnancy and subsequent care of the child (Table 2). The best informed group consisted of those women who had
already had children and planned to have more.
In the main, advice was given by hospital specialists (Table 3). Of women receiving advice 58% stated this was their main
source of information. General practitioners were mentioned by a third. Of all the women who received advice, 17% were
advised by the British Epilepsy Association (BEA) which might be expected in this group of BEA members. Overall the
women felt there was a need for more information about epilepsy and pregnancy.
Table 1: Advice given about pregnancy and epilepsy.
All women Women with Women planning to have children in
children next 2 yrs >2 yrs
n 1855 880 169 272
No advice 637 (34%) 332 (38%) 34 (20%) 61 (22%)
Not discussed with anyone 459 (25%) 153 (17%) 11 (7%) 103 (38%)
Any mention of the effects of
medication 439 (23%) 100 (11%) 56 (33%) 67 (25%)
teratogenicity 149 (7%) 51 (5%) 24 (15%) 23 (12%)
Other advice
to discuss with a doctor 158 (9%) 34 (4%) 31 (18%) 58 (21%)
pre-pregnancy counselling 105 (6%) 21 (2%) 17 (10%) 41 (15%)
folic acid supplements 87 (5%) 42 (5%) 34 (20%) 22 (8%)
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Table 2: Concerns about pregnancy and childcare of women intending to have children in the subsequent 2 years.
No previous children Previous children
n 117 52
Not given enough information 64 (55%) 15 (28%)
Worried about effects of medication on 90 (77%) 35 (68%)
unborn child
Anxious about increased seizures whilst 75 (64%) 29 (56%)
pregnant
Worried about whether they were able to 28 (24%) 7 (14%)
have children because of epilepsy
Worried that their medication might 47 (40%) 13 (25%)
affect their ability to have children
Table 3: Source of advice.
All women Women with children Women planning to have
a child in next 2 years
n 1885 880 169
Hospital specialist 435 (23%) 197 (22%) 92 (54%)
General practitioner 249 (13%) 134 (15%) 53 (31%)
British Epilepsy Association 121 (7%) 52 (6%) 19 (11%)
Friend/relative 31 (2%) 9 (1%) 2 (1%)
Nurse 21 (1%) 10 (1%) 6 (4%)
Media 20 (1%) 6 (1%) 2 (1%)
Library 14 (1%) 4 (0.5%) 1 (0.5%)
Found out own information 7 (0.5%) 4 (0.5%) 1 (0.5%)
